RepliCel adds an independent director | BioSpace
The Board of Directors strengthens its independence monitoring and updates its stock options
VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2), (“RepliCel” or the “Company”), a company that develops next-generation technologies in aesthetics and orthopedics, is pleased to announce the appointment of Gary Boddington to the Board of Directors.
Gary Boddington is currently the CEO of PlayWize Technology Inc. He has experience building and leading global businesses, exploring new markets, launching new products and raising capital. Gary has worked with founders, shareholders and boards of directors of public and private entities. He founded a business intelligence company which was acquired by an FTSE 100 company, was an early team member of the first publicly traded blockchain company in Canada who carried out projects pioneering pilots with big brands globally, and most recently was an independent director of a Vancouver financial technology company with capital of $ 100. over a million releases. Gary brings to RepliCel’s Board of Directors his passion for global business development and digital transformation, with his enthusiasm and experience in SportsTech, Fintech, Blockchain, Business Intelligence, Artificial Intelligence and Entrepreneurship to the discussions.
The Company also announced that it had granted a total of 1,715,000 stock options (each, a “Option”) To certain directors, officers, employees and consultants for the purchase of up to 1,715,000 common shares of the Company under its stock option plan. Each option may be exercised for a period of 5 years beginning June 14, 2021, at a price of $ 0.40 per common share. 735,000 of these options vest immediately and 980,000 of these options vest at 12.5% per quarter for eight quarters.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for cosmetic and orthopedic conditions affecting what the company estimates to be approximately one in three people in industrialized countries, including aging / sun damaged skin, baldness and chronic degeneration of the tendons. These conditions, often associated with aging, are caused by a deficit of healthy cells necessary for normal tissue healing and function. These cell therapy product candidates are based on the innovative RepliCel technology, using cell populations isolated from a patient’s healthy hair follicles.
The Company’s product portfolio includes RCT-01 for tendon repair, RCS-01 for skin rejuvenation and RCH-01 for hair restoration. RCH-01 is exclusively licensed in Asia to Shiseido Company. RepliCel retains the rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel retains the rights to these products outside of Greater China.
RepliCel has also developed a proprietary injection device, the RCI-02, and associated consumables, which are expected to improve the delivery of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights to the RCI-02 device and consumables in Greater China for dermatological applications and is expected to first launch the product in Hong Kong upon approval for market launch in the United States or in Europe.
Please visit www.replicel.com for more information.
• RepliCel’s three cell therapy products have now been tested in more than 100 patients in four countries on three continents after being successfully evaluated by three regulatory bodies.
• RepliCel now has key strategic partners in the United States, China and Japan, each of which is now investing heavily in the continuation of clinical trials and the development of RepliCel’s products for their markets. Data from each of the clinical programs will strengthen product development initiatives for RepliCel and its other partners around the world.
For more information please contact:
Lee Buckler, CEO and Chairman
SOURCE: RepliCel Life Sciences, Inc.
See the source version on accesswire.com: